Abstract:Background The interplay between the gut microbiome and immune responses in cancer remains poorly understood. We showed that gut microbiome changes are closely associated with development of lung adenocarcinoma (LUAD) in a human-relevant, tobacco-associated mouse model (Gprc5a-/-; G).1 Knockout of the antimicrobial protein Lcn2 (Gprc5a-/-/Lcn2-/-; GL) further reduced microbial diversity while enhancing inflammation and tumor development.1 We thus hypothesized that microbial dysbiosis in the gut, such as that incurred by loss of Lcn2, may exacerbate LUAD development and influence response to immune checkpoint blockade (ICB). Methods We used fecal microbiota transfer (FMT) in syngeneic and tobacco carcinogenesis models. Gut microbiome composition was assessed using 16S rDNA-Seq analysis, chemokines were quantified in murine sera, and the tumor immune microenvironment (TIME) and gut immune milieu were comprehensively studied using single-cell RNA-sequencing and flow cytometry. Results Syngeneic G mice receiving FMT from GL donors (G < GL) exhibited significantly increased tumor growth compared to G < G mice. This effect was recapitulated in an independent syngeneic model (KrasG12D LKR13 cells in wild-type mice) and tobacco carcinogen-exposed G < GL mice. Analysis of fecal pellets using 16S rDNA-Seq revealed significant differences in gut beta diversity between G < G and G < GL mice, with elevated abundance of tumor-promoting Alistipes2 and reduced levels of immunotherapy-favorable taxa Ruminoccocus and Akkermansia.3 Flow cytometry analysis of the colonic lamina propria demonstrated an inflamed environment in G < GL mice with increased inflammatory immune cell frequency. This local gut inflammation was accompanied by a systemic inflammatory response, as indicated by elevated inflammatory chemokines in the sera. Single-cell RNA-sequencing and flow cytometry analysis of tumors revealed an enhanced immunosuppressive phenotype in the TIME of G < GL mice, including increased fractions of T regulatory and exhausted T cells, along with reduced levels of activated T cells. Flow cytometry confirmed enhanced immunosuppression in G < GL mice, including increased fractions of myeloid-derived suppressor cells in the TIME. The dysbiotic gut, with its associated systemic inflammation and immunosuppression of the TIME, significantly impacted the response to ICB, with G < GL mice demonstrating reduced response and sensitivity to anti-PD1 treatment compared to G < G mice. Conclusions Our findings show that gut microbiome dysbiosis fosters lung cancer development by promoting immunosuppression, perhaps via a local and systemic gut microbiota-immune system crosstalk (figure 1). Modulating the gut microbiome may offer promising strategy for interception or early treatment of lung cancer. Acknowledgements Supported in part by National Cancer Institute (NCI) grants R01CA205608 and R01CA248731 (to H. Kadara). References Finnicum CT, Rahal Z, Hassane M, Treekitkarnmongkol W, Sinjab A, Morris R, Liu Y, Tang EL, Viet S, Petersen JL, et al. Pathogenesis of Tobacco-Associated Lung Adenocarcinoma Is Closely Coupled with Changes in the Gut and Lung Microbiomes. Int J Mol Sci. 2022;23(18):10930. Available online: https://doi.org/10.3390/ijms231810930 Moschen AR, Gerner RR, Wang J, Klepsch V, Adolph TE, Reider SJ, Hackl H, Pfister A, Schilling J, Moser PL, Kempster SL, Swidsinski A, Orth Höller D, Weiss G, Baines JF, Kaser A, Tilg H. Lipocalin 2 Protects from Inflammation and Tumorigenesis Associated with Gut Microbiota Alterations. Cell Host Microbe. 2016;19(4):455–469. doi: 10.1016/j.chom.2016.03.007 Cascone T, William WN, Weissferdt A, et al. Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial. Nat Med. 2021;27(3):504–514. doi: 10.1038/s41591–020-01224–2

Abstract 6680: High-fiber diet induces favorable gut microbiota, reduces immunosuppression, and inhibits lung cancer development

Abstract 2883: Gut Microbiome Dysbiosis Promotes Immune Suppression and Lung Cancer Development

Colorectal carcinogenesis in Smad4/SPTBN1 mutants alter the intestinal microbiome and resistance to 5FU.

Dietary low-fiber promotes resistance to immune checkpoint inhibitor immunotherapy in the LSL-KrasG12D Lung Cancer Model

1330 Gut Microbiome Dysbiosis Promotes Immune Suppression and Lung Cancer Development

Abstract 4435: A causal modeling platform for testing lifestyle interventions on the microbiome and response to immunotherapy

Gut microbiome affects the response to immunotherapy in non-small cell lung cancer

High Soluble Fiber Promotes Colorectal Tumorigenesis Through Modulating Gut Microbiota and Metabolites in Mice

Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response

Inflammation mediated by gut microbiome alterations promotes lung cancer development and an immunosuppressed tumor microenvironment

Abstract 6060: Can the gut microbiota both radiosensitize tumors and spare normal tissue toxicity

Abstract 2794: Consumption of dietary fiber correlates with a significant increase in a-diversity in the intestinal Microbiome of allo-HCT recipients and with lower GVHD-lethality in pre-clinical models

Abstract 4243: Dietary flavonoids prevent colon tumor formation in ApcMin/+ mice in a microbiome- and sex-dependent manner

Abstract 6692: Intermittent fasting-remodeled gut microbiota improves anti-tumor immunity in pancreatic cancer

Abstract 1825: A bacterial consortium engineered from feces of patients responding to anti-PD1 treatment mediates tumor response through IFNγ in non-small cell lung cancer

Abstract 1423: Harnessing the gut microbiome to modulate immune checkpoint blockade response in triple-negative breast cancer

The Preventive Effects of Inulin, Cellulose, and Their Mixture on Colorectal Cancer Liver Metastasis in Mice by Regulating Gut Microbiota.

Effects of Dietary Interventions on Gut Microbiota in Humans and the Possible Impacts of Foods on Patients’ Responses to Cancer Immunotherapy

Correlations of Dietary Fiber with Intestinal Microbiome and Outcomes in Allogeneic Hematopoietic Cell Transplantation

Dietary Fiber Treatment Corrects the Composition of Gut Microbiota, Promotes SCFA Production, and Suppresses Colon Carcinogenesis

Abstract 4298: the Gut Microbiome is Associated with Clinical Responses to Anti-Pd-1 Immunotherapy in Gastrointestinal Cancer Patients in China